Regeneron Pharmaceuticals (REGN) is currently in a complex situation. While some investment firms have increased their shares, there are also legal concerns for the company. Rosen Global Investor Counsel and Robbins LLP urged REGN shareholders to consider a class-action lawsuit that investors could lead. A similar alert was issued by Bronstein, Gewirtz, and Grossman, LLC. Despite this, some investors have been noted to buy more stakes, such as Exchange Traded Concepts LLC and BDF Gestion. However, others reduced their holdings, like Transform Wealth LLC and ARS Investment Partners LLC. Regeneron's high-dose Eylea sales disappointed, affecting the company's stock performance against competitors. Despite this, Jim Cramer affirmed the company's capacity to develop new medicines. Regeneron also recently announced the finalists for their $1.8M Science Talent Search Competition, highlighting their contribution to future scientific breakthroughs. Lastly, the company is being tested for its investigational antibody cocktail, REGN-COV2, in a phase 3 trial for COVID-19 recovery in the UK.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 14 Sep 2020 07:00:00 GMT to Sat, 25 Jan 2025 13:52:49 GMT -
Rating -1
- Innovation 5
- Information 7
- Rumor -4
